SEC Form 4 · accession 0001140361-15-012536
Raptor Pharmaceutical Corp · RPTP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher M Starr
Director
Period of report
Mar 16, 2015
Accepted (ET)
Mar 18, 2015 · 6:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070698
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 16, 2015 | M | 30,021 | $3.54 | A | 731,065 | D | |
| Common StockF1,F2 | Mar 16, 2015 | S | 30,021 | $11.7106 | D | 701,044 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock options (right to buy)F1,F3 | $3.54 | Mar 16, 2015 | M | 30,021 | D | — | Nov 22, 2020 | Common Stock | 30,021 | 20,033 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 20, 2014.
- F2This transaction was executed in multiple trades at prices ranging from $11.3804 to $12.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Fully vested and exercisable.